Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASA-1
- Development stage
- Unknown
- Lead developer
- Adjuvax
- Modality
- Small Molecules
01
Overview
ASA-1 is a semisynthetic saponin-based vaccine adjuvant developed by Adjuvax. It is designed specifically for veterinary applications to enhance immune responses when formulated with systemic or mucosal veterinary vaccines. Derived as a semisynthetic analog of natural saponins, ASA-1 aims to provide a potent, cost-effective, and structurally defined alternative to traditional adjuvants like QS-21, offering improved chemical stability and reduced toxicity. It is currently available for purchase as an adjuvant component and is in preclinical development for use in veterinary vaccine formulations.
- Other names
- ASA-1 adjuvantASA1 adjuvantASA 1 adjuvant
Beyond the preview
Go deeper on ASA-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASA-1.